Memorial Sloan Kettering Partners with Quest for Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb) – Memorial Sloan Kettering Cancer Center has partnered with Quest Diagnostics to use molecular testing of patients' tumors to provide better treatment options and understand the genomic underpinnings of the disease.

In the first phase of the collaboration, Memorial Sloan Kettering will provide contextual information about the mutations identified in a next-generation sequencing-based test developed by Quest and will contribute to the clinical annotation report provided to physicians.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.